MCID: PRS045
MIFTS: 50

Prostatic Hypertrophy

Categories: Reproductive diseases

Aliases & Classifications for Prostatic Hypertrophy

MalaCards integrated aliases for Prostatic Hypertrophy:

Name: Prostatic Hypertrophy 12 15 74
Benign Prostatic Hypertrophy 74
Prostatic Hyperplasia 74

Classifications:



External Ids:

Disease Ontology 12 DOID:11132

Summaries for Prostatic Hypertrophy

MalaCards based summary : Prostatic Hypertrophy, also known as benign prostatic hypertrophy, is related to prostatic hyperplasia, benign and prostate cancer, and has symptoms including prostatism An important gene associated with Prostatic Hypertrophy is KLK3 (Kallikrein Related Peptidase 3), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs Alfuzosin and Tamsulosin have been mentioned in the context of this disorder. Affiliated tissues include prostate, heart and testes, and related phenotypes are cardiovascular system and endocrine/exocrine gland

Related Diseases for Prostatic Hypertrophy

Diseases related to Prostatic Hypertrophy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 158)
# Related Disease Score Top Affiliating Genes
1 prostatic hyperplasia, benign 30.1 ADRA1A AR KLK3
2 prostate cancer 29.5 AR CYP19A1 EGF EGFR ESR1 KLK3
3 muscle hypertrophy 10.5
4 prostate cancer, hereditary, 8 10.4
5 prostate cancer, hereditary, 6 10.4
6 male reproductive organ benign neoplasm 10.3 CYP19A1 KLK3
7 vestibular gland benign neoplasm 10.3 ESR1 PGR
8 bartholin's gland adenoma 10.3 ESR1 PGR
9 vulvar syringoma 10.3 ESR1 PGR
10 lung leiomyoma 10.3 ESR1 PGR
11 glassy cell carcinoma of the cervix 10.3 ESR1 PGR
12 postmenopausal atrophic vaginitis 10.3 AR ESR1
13 vulvar benign neoplasm 10.3 ESR1 PGR
14 nodular prostate 10.3 AR KLK3
15 trigonitis 10.3 ESR1 PGR
16 vaginitis 10.3 AR ESR1
17 vulvar leiomyoma 10.3 ESR1 PGR
18 predominantly cortical thymoma 10.3 ESR1 PGR
19 breast medullary carcinoma 10.3 ESR1 PGR
20 androgen insensitivity, partial 10.3 AR CYP19A1
21 bartholin's gland benign neoplasm 10.3 ESR1 PGR
22 progesterone resistance 10.3 ESR1 PGR
23 cribriform carcinoma 10.3 ESR1 PGR
24 transsexualism 10.3 AR CYP19A1
25 endometrial mucinous adenocarcinoma 10.3 ESR1 PGR
26 adenoid basal cell carcinoma 10.3 ESR1 PGR
27 sebaceous adenoma 10.3 EGF ESR1
28 benign metastasizing leiomyoma 10.3 CYP19A1 PGR
29 deep angioma 10.3 ESR1 PGR
30 alopecia, androgenetic, 1 10.3 AR CYP19A1
31 synchronous bilateral breast carcinoma 10.3 ESR1 PGR
32 female reproductive endometrioid cancer 10.3 ESR1 PGR
33 cervical carcinosarcoma 10.2 ESR1 PGR
34 intramuscular hemangioma 10.2 ESR1 PGR
35 glycogen-rich clear cell breast carcinoma 10.2 ESR1 PGR
36 cervical clear cell adenocarcinoma 10.2 ESR1 PGR
37 retinitis pigmentosa 47 10.2 ESR1 PGR
38 endometrial disease 10.2 CYP19A1 ESR1
39 corneal abscess 10.2 AR PGR
40 retinitis pigmentosa 20 10.2 ESR1 PGR
41 bartholin's gland disease 10.2 AR PGR
42 calcifying aponeurotic fibroma 10.2 EGF PGR
43 hermaphroditism 10.2 AR SRY
44 adenosarcoma 10.2 ESR1 PGR
45 ovarian benign neoplasm 10.2 CYP19A1 SRY
46 endometrial stromal nodule 10.2 CYP19A1 PGR
47 breast benign neoplasm 10.2 ESR1 PGR
48 thoracic benign neoplasm 10.2 ESR1 PGR
49 androgenic alopecia 10.2 AR CYP19A1 KLK3
50 papillary hidradenoma 10.2 AR PGR

Comorbidity relations with Prostatic Hypertrophy via Phenotypic Disease Network (PDN): (show top 50) (show all 52)


Acute Cystitis Acute Kidney Failure
Anthracosis Asbestosis
Balanoposthitis Bladder Cancer
Bladder Disease Bladder Neck Obstruction
Chronic Kidney Failure Chronic Myocardial Ischemia
Cystitis Cystitis Cystica
Epididymo-Orchitis First-Degree Atrioventricular Block
Generalized Atherosclerosis Gout
Hydronephrosis Infected Hydrocele
Interstitial Cystitis Ischemic Heart Disease
Kidney Disease Left Bundle Branch Hemiblock
Lipoma of Spermatic Cord Low Compliance Bladder
Nephrolithiasis, X-Linked Recessive, with Renal Failure Neurogenic Bladder
Parkinson Disease, Late-Onset Pelvic Varices
Penile Disease Peyronie's Disease
Pinta Disease Pneumoconiosis
Postinflammatory Pulmonary Fibrosis Prostate Calculus
Prostate Cancer Prostate Carcinoma in Situ
Prostate Disease Prostatitis
Prostatocystitis Renal Pelvis Carcinoma
Right Bundle Branch Block Silicosis
Spermatocele Ureter, Cancer of
Ureterolithiasis Urethral Benign Neoplasm
Urethral Calculus Urethral Stricture
Urethritis Urinary Tract Obstruction

Graphical network of the top 20 diseases related to Prostatic Hypertrophy:



Diseases related to Prostatic Hypertrophy

Symptoms & Phenotypes for Prostatic Hypertrophy

UMLS symptoms related to Prostatic Hypertrophy:


prostatism

MGI Mouse Phenotypes related to Prostatic Hypertrophy:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.98 ADRA1A AR CD36 CYP19A1 EGFR ESR1
2 endocrine/exocrine gland MP:0005379 9.97 AR CD36 CYP19A1 EGF EGFR ESR1
3 immune system MP:0005387 9.97 AR CD36 CYP19A1 EGF EGFR ESR1
4 adipose tissue MP:0005375 9.93 AR CD36 CYP19A1 EGFR ESR1 PCNA
5 digestive/alimentary MP:0005381 9.88 AR CD36 CYP19A1 EGF EGFR ESR1
6 integument MP:0010771 9.73 AR CYP19A1 EGF EGFR ESR1 PGR
7 muscle MP:0005369 9.7 ADRA1A AR CD36 CYP19A1 EGFR ESR1
8 renal/urinary system MP:0005367 9.43 ADRA1A AR CD36 CYP19A1 EGFR ESR1
9 reproductive system MP:0005389 9.17 AR CYP19A1 EGF EGFR ESR1 PCNA

Drugs & Therapeutics for Prostatic Hypertrophy

Drugs for Prostatic Hypertrophy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 110)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Alfuzosin Approved, Investigational Phase 4,Phase 3,Not Applicable 81403-80-7 2092
2
Tamsulosin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 106133-20-4 129211
3
Mirabegron Approved Phase 4 223673-61-8 9865528
4
Silodosin Approved Phase 4 160970-54-7
5
Mivacurium Approved Phase 4 133814-19-4, 106791-40-6 5281042
6
Atracurium Approved, Experimental, Investigational Phase 4 64228-79-1 47319
7
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
8
Testosterone undecanoate Approved, Investigational Phase 4,Phase 2 5949-44-0
9
Methyltestosterone Approved Phase 4,Phase 2 58-18-4 6010
10
Testosterone Approved, Experimental, Investigational Phase 4,Phase 3,Phase 2 58-22-0, 481-30-1 10204 6013
11
Dihydrotachysterol Approved Phase 4 67-96-9 5311071 5281010
12
Dutasteride Approved, Investigational Phase 4,Phase 3,Not Applicable 164656-23-9 6918296 152945
13
Testosterone enanthate Approved Phase 4,Phase 2 315-37-7 9416
14
Dihydrotestosterone Illicit, Investigational Phase 4 521-18-6 10635
15 Adrenergic alpha-1 Receptor Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Adrenergic Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Adrenergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
19 Adrenergic alpha-Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Mitogens Phase 4,Not Applicable
21 Adrenergic Agonists Phase 4,Not Applicable
22 Adrenergic beta-3 Receptor Agonists Phase 4
23 Adrenergic beta-Agonists Phase 4
24 Neuromuscular Nondepolarizing Agents Phase 4
25 Neuromuscular Agents Phase 4,Phase 3
26 Anesthetics Phase 4,Not Applicable
27 Cholinergic Antagonists Phase 4,Phase 2,Phase 3
28 Peripheral Nervous System Agents Phase 4,Phase 3,Not Applicable
29 Neuromuscular Blocking Agents Phase 4
30 Cholinergic Agents Phase 4,Phase 3,Phase 2
31 Solifenacin succinate Phase 4 242478-38-2
32 Muscarinic Antagonists Phase 4,Phase 2,Phase 3
33 Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
34 Hormones Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
35 5-alpha Reductase Inhibitors Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
36 Anabolic Agents Phase 4,Phase 2
37 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
38 Testosterone 17 beta-cypionate Phase 4,Phase 2
39 Antineoplastic Agents, Hormonal Phase 4,Phase 2
40 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
41 Androgens Phase 4,Phase 3,Phase 2,Not Applicable
42 Parasympatholytics Phase 4
43
Cetrorelix Approved, Investigational Phase 3 120287-85-6 25074887 16129715
44
Acetylcholine Approved, Investigational Phase 3 51-84-3 187
45
Finasteride Approved Phase 3,Phase 1,Phase 2,Not Applicable 98319-26-7 57363
46
Doxazosin Approved Phase 3 74191-85-8 3157
47
Prazosin Approved Phase 3,Phase 1,Not Applicable 19216-56-9 4893
48
Norepinephrine Approved Phase 3 51-41-2 439260
49 Antihypertensive Agents Phase 3,Phase 1,Not Applicable
50 Fertility Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 85)
# Name Status NCT ID Phase Drugs
1 Multicenter Prospective Study on the Changes of Sexual Function Following Treatment With Alfuzosin (Xatral XL®) in Patients With Benign Prostate Hypertrophy Completed NCT00542165 Phase 4 Alfuzosin
2 A Phase 4 Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Male Subjects With Overactive Bladder (OAB) Symptoms, While Taking the Alpha Blocker for Benign Prostatic Hypertrophy (BPH) Completed NCT02656173 Phase 4 Mirabegron;Placebo;Tamsulosin
3 Safety and Efficacy of QD Versus BID Silodosin With Lower Urinary Tract Symptoms Suggestive of BPH Completed NCT01260129 Phase 4 Silodosin;Silodosin
4 Effect of Deep BLock on Intraoperative Surgical Conditions Completed NCT01631149 Phase 4 Surgical block (rocuronium; atracurium/mivacurium);Surgical block (rocuronium; atracurium/mivacurium)
5 Solifenacin as Add-on Therapy for Overactive Bladder Symptoms in Men Treated for Benign Prostatic Hyperplasia Completed NCT00771394 Phase 4 Tamsulosin hydrochloride;Solifenacin succinate
6 Efficacy Study for Use of Dutasteride (Avodart) With Testosterone Replacement Completed NCT00752869 Phase 4 dutasteride;placebo
7 Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer Completed NCT00375765 Phase 4 Dutasteride
8 Pilot Trial Of Urinary Nerve Growth Factor (NGF) As Biomarker for Male Lower Urinary Tract Symptoms Completed NCT01457573 Phase 4 Tamsulosin;Solifenacin
9 Preoperative Administration of Tamsulosin for Prevention of Post Operative Urinary Retention in Males Undergoing Elective Inguinal Hernia Repair Enrolling by invitation NCT02958878 Phase 4 Tamsulosin;Placebo Oral Capsule
10 Cetrorelix Pamoate in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH) Completed NCT00663858 Phase 3 Cetrorelix 78+78;Cetrorelix 78 + Placebo
11 The Safety and Efficacy of Ozarelix to Treat Men With Lower Urinary Tract Symptoms Due to Enlargement of the Prostate Completed NCT00427219 Phase 2, Phase 3 Ozarelix/Placebo;Placebo
12 A-botulinic Toxin for Symptomatic Benign Prostate Hypertrophy Completed NCT01275521 Phase 3 BONT-A intra-prostatic injection;Optimized medical BPH treatment
13 Cetrorelix Pamoate IM Regimens in Patients With Symptomatic Benign Prostatic Hyperplasia (BPH) Completed NCT00670306 Phase 3 Cetrorelix Pamoate
14 Study to Assess the Efficacy of Medi-Tate iTind Device Completed NCT02145208 Phase 3
15 Medical Therapy of Prostatic Symptoms Completed NCT00021814 Phase 3 Doxazosin;Finasteride;Doxazosin placebo;Finasteride placebo
16 Clinical Trial in Males With BPH (Enlarged Prostate) Completed NCT00029822 Phase 3 Alfuzosin (SL770499)
17 "REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk Completed NCT00056407 Phase 3 Dutasteride;Placebo
18 Combined Behavioral and Drug Treatment of Overactive Bladder in Men Completed NCT01175382 Phase 2, Phase 3 Tolterodine + tamsulosin
19 Predicting Responses to PTSD Treatment With Iris and Cardiovascular Tests Recruiting NCT03539614 Phase 3 Prazosin;Placebo
20 Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH) Terminated NCT00449150 Phase 3 Cetrorelix 78 mg + 78 mg;Cetrorelix 78 mg + 52 mg;Placebo
21 H-36731: Finasteride in Management of Elevated Red Blood Cells Withdrawn NCT02548117 Phase 3 Finasteride
22 A 20-Week Study of a New Treatment for Men With Benign Prostatic Hyperplasia (BPH). Unknown status NCT00044226 Phase 2 ML-04A
23 Vardenafil in Greenlight(TM) Laser Surgery of Benign Prostate Hypertrophy Completed NCT00461123 Phase 2 Vardenafil (Levitra, BAY38-9456);Placebo
24 Effects of Tadalafil Once a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia Completed NCT00386009 Phase 2 Tadalafil;Placebo
25 Safety/Tolerability Study of Alcohol Injection for Treatment of BPH (Enlarged Prostate) Completed NCT00037141 Phase 1, Phase 2 dehydrated alcohol
26 A Clinical Study to Determine Factors Affecting Absorption and Serum Levels of Lycopene After Supplementation Completed NCT00154843 Phase 2 Lycopene
27 Extension Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy Completed NCT01227993 Phase 1, Phase 2 Finasteride
28 5-Alpha Reductase and Anabolic Effects of Testosterone Completed NCT00475501 Phase 2 Testosterone Enanthate;Finasteride
29 Prostate Embolization for Massive Benign Prostatic Hypertrophy (BPH) Recruiting NCT02676544 Phase 1, Phase 2
30 Use of Autologous Adipose-Derived Stem/Stromal Cells (AD-cSVF) in Symptomatic Benign Prostate Hypertrophy Recruiting NCT02961114 Phase 1, Phase 2
31 Optilume™ BPH Prostatic Drug Coated Balloon Dilation Catheter Active, not recruiting NCT03423979 Phase 2 Paclitaxel
32 Feasibility and Toxicity of Degarelix for Prostate Downsizing Prior to Permanent Seed Prostate Brachytherapy Active, not recruiting NCT01446991 Phase 2 Degarelix;Degarelix
33 Prostate Artery Embolization as a Treatment for Benign Prostatic Hyperplasia in Men With Prostates Larger Than 90 Grams Terminated NCT02396420 Phase 2
34 Dose Response Study of VA106483 in Males With Nocturia and Benign Prostatic Hypertrophy (BPH) Completed NCT01330927 Phase 1 VA106483
35 A Clinical Trial to Evaluate the Effects of Food on the Bioavailability of CKD-397 in Healthy Male Subjects Completed NCT02615782 Phase 1 CKD-397
36 Prazosin Use in Adults With Anxiety Disorders Recruiting NCT03894345 Phase 1 Prazosin
37 Uroxatral in Men With Benign Prostate Hypertrophy (BPH) and Erectile Dysfunction (ED) Unknown status NCT00256399 Not Applicable Alfuzosin 10 mg
38 Comparison of Different Energy Sources During TUR-P Unknown status NCT02533687 Not Applicable
39 Prognostic Value of the Urinary Nerve Growth Factor in the Patients With Benign Prostatic Hyperplasia Unknown status NCT01781117 Not Applicable
40 The Effect of Anterior Corneal Incisions on Intraoperative Floppy Iris Syndrome (IFIS) Incidence and Severity in Tamsulosin Treated Cataract Patients Unknown status NCT01070602 Not Applicable
41 The Effectiveness of 18F-fluorocholine Positron Emission Tomography (PET) in Detecting, Staging and Following-up Prostate Cancer Unknown status NCT01089881
42 Rezum FIM Optimization Unknown status NCT02940392 Not Applicable
43 Rezum I Pilot Study for BPH Unknown status NCT02943070 Not Applicable
44 Observational Study to Investigate the Effectiveness of Eprosartan on Pulse Pressure (Teveten_MS) Unknown status NCT02024100
45 Benign Prostatic Hypertrophy Treatment Patterns & Outcomes: Marketscan Completed NCT01323998 5ARI;AB
46 MRI and Magnetic Resonance Spectroscopy Imaging in Patients Receiving Dutasteride for Benign Prostatic Hypertrophy and Low-Risk Prostate Cancer Completed NCT00706966 Not Applicable dutasteride
47 Plasmakinetic Enucleation of the Prostate to Treat Benign Prostatic Hypertrophy Patients With Large Prostate Completed NCT01637701 Not Applicable
48 Safety and Efficacy of OCL 503 in Prostate Artery Embolization Completed NCT02509975 Not Applicable
49 Assessing the Impact of the PVP With Greenlight Laser Using Prostatic MRI and Contrast-enhanced Ultrasound Completed NCT01732991 Not Applicable
50 The Effect of Spermatic Vein Embolization on Prostatic Hypertrophy Completed NCT00639899 Not Applicable

Search NIH Clinical Center for Prostatic Hypertrophy

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Genetic Tests for Prostatic Hypertrophy

Anatomical Context for Prostatic Hypertrophy

MalaCards organs/tissues related to Prostatic Hypertrophy:

42
Prostate, Heart, Testes, Kidney, Bone, Smooth Muscle, Ovary

Publications for Prostatic Hypertrophy

Articles related to Prostatic Hypertrophy:

(show top 50) (show all 569)
# Title Authors Year
1
Drugs for benign prostatic hypertrophy. ( 30410211 )
2018
2
Silodosin for benign prostatic hypertrophy. ( 30116085 )
2018
3
Benign prostatic hypertrophy: Pycnogenol® supplementation improves prostate symptoms and residual bladder volume. ( 29947491 )
2018
4
Emerging, newly-approved treatments for lower urinary tract symptoms secondary to benign prostatic hypertrophy. ( 29679999 )
2018
5
Investigational procedures in benign prostatic hypertrophy. ( 29528973 )
2018
6
Donegal Going against the Flow: National Differences in Long-Term Urinary Catheterisation Rates in Men (> 65 Years) With Benign Prostatic Hypertrophy. ( 29372955 )
2017
7
Ageratum conyzoides L. inhibits 5-alpha-reductase gene expression in human prostate cells and reduces symptoms of benign prostatic hypertrophy in otherwise healthy men in a double blind randomized placebo controlled clinical study. ( 29048765 )
2017
8
The androgen receptor plays different roles in macrophage-induced proliferation in prostate stromal cells between transitional and peripheral zones of benign prostatic hypertrophy. ( 28694768 )
2017
9
Can the UroLift prostatic implant device treat the symptoms of benign prostatic hypertrophy, avoid sexual dysfunction and reduce hospital TURP waiting times? A single centre, single surgeon experience and review of the literature. ( 28609136 )
2017
10
Minimally invasive surgical therapies for benign prostatic hypertrophy: The rise in minimally invasive surgical therapies. ( 28593165 )
2017
11
Case-Control Study of Intra-arterial Verapamil for Intraprostatic Anastomoses to Extraprostatic Arteries in Prostatic Artery Embolization for Benign Prostatic Hypertrophy. ( 28506701 )
2017
12
Investigating the link between benign prostatic hypertrophy, BMI and type 2 diabetes mellitus. ( 28433616 )
2017
13
Lower urinary tract symptoms/benign prostatic hypertrophy and vascular function: Role of the nitric oxide-phosphodiesterase type 5-cyclic guanosine 3',5'-monophosphate pathway. ( 28332240 )
2017
14
Prostate Artery Embolization for Complete Urinary Outflow Obstruction Due to Benign Prostatic Hypertrophy. ( 27853823 )
2017
15
Treatment of lower urinary tract symptoms in benign prostatic hypertrophy with α-blockers. ( 27629686 )
2016
16
Inhibitory Activities of Phenolic Compounds Isolated from Adina rubella Leaves Against 5α-Reductase Associated with Benign Prostatic Hypertrophy. ( 27399661 )
2016
17
Re: Stroke Associated with Alpha Blocker Therapy for Benign Prostatic Hypertrophy. ( 27321530 )
2016
18
Varicocele: the origin of benign prostatic hypertrophy? Testosterone dosages in the periprostatic plexus. ( 26290288 )
2016
19
Clinical Outcomes of Transurethral Enucleation with Bipolar for Benign Prostatic Hypertrophy. ( 26662662 )
2015
20
The Role of Minimally Invasive Surgical Techniques in the Management of Large-gland Benign Prostatic Hypertrophy. ( 26543428 )
2015
21
Supplementary management of benign prostatic hypertrophy with Prostaquil. An 8-week registry. ( 26492588 )
2015
22
The Impact of Medical and Surgical Treatment for Benign Prostatic Hypertrophy on Erectile Function. ( 26438220 )
2015
23
Kidney transplant complications from undiagnosed benign prostatic hypertrophy. ( 25832848 )
2015
24
Effects of α-blocker therapy on active duty military and military retirees for benign prostatic hypertrophy on diabetic complications. ( 25735029 )
2015
25
Estrogen receptor beta agonist LY500307 fails to improve symptoms in men with enlarged prostate secondary to benign prostatic hypertrophy. ( 25348255 )
2015
26
Bipolar transurethral resection versus monopolar transurethral resection for benign prostatic hypertrophy: a systematic review and meta-analysis. ( 24754254 )
2014
27
Surgical therapy for benign prostatic hypertrophy/bladder outflow obstruction. ( 24744521 )
2014
28
Bilateral ureteral obstruction revealing a benign prostatic hypertrophy: a case report and review of the literature. ( 24513237 )
2014
29
Re: a phase II randomised double-blind placebo-controlled clinical trial investigating the efficacy and safety of ProstateEZE Max: a herbal medicine preparation for the management of symptoms of benign prostatic hypertrophy. ( 25629105 )
2014
30
Efficacy of Long-Term Daily Dosage of Alfuzosin 10 mg upon Sexual Function of Benign Prostatic Hypertrophy Patients: Two-Year Prospective Observational Study. ( 25606561 )
2014
31
Preparation, characterization and stability study of dutasteride loaded nanoemulsion for treatment of benign prostatic hypertrophy. ( 25587300 )
2014
32
Re: Editorial comment on constitutional, organopathic and combined homeopathic treatment of benign prostatic hypertrophy: a clinical trial: S. A. Kaplan J Urol 2013; 190: 1818-1819. ( 24892642 )
2014
33
Tadalafil and benign prostatic hypertrophy. Too risky. ( 24860894 )
2014
34
Correlation of transrectal and transabodominal ultrasound measurement of transition zone volume with post-operative enucleated adenoma volume in benign prostatic hypertrophy. ( 24876907 )
2013
35
Re: Constitutional, organopathic and combined homeopathic treatment of benign prostatic hypertrophy: a clinical trial. ( 24120797 )
2013
36
A phase II randomised double-blind placebo-controlled clinical trial investigating the efficacy and safety of ProstateEZE Max: a herbal medicine preparation for the management of symptoms of benign prostatic hypertrophy. ( 23642948 )
2013
37
Alpha-1 adrenergic antagonists in aircrew for the treatment of benign prostatic hypertrophy. ( 23305000 )
2013
38
Successful minimally-invasive management of a case of giant prostatic hypertrophy associated with recurrent nephrogenic adenoma of the prostate. ( 23565707 )
2013
39
Constitutional, organopathic and combined homeopathic treatment of benign prostatic hypertrophy: a clinical trial. ( 23089217 )
2012
40
On call. As a retired physician, I particularly appreciate "Harvard Men's Health Watch" since it's an easy way for me to learn about new developments in medicine. As a 78-year-old man with an enlarged prostate, I'm particularly interested in your fine articles about BPH. But if memory serves me right, we called the condition "benign prostatic hypertrophy" when I was in practice, but now you call it "benign prostatic hyperplasia." What's the difference? ( 22670285 )
2012
41
American Urological Association and European Association of Urology guidelines in the management of benign prostatic hypertrophy: revisited. ( 22123290 )
2012
42
Analysis of the Pressure-Flow Study in Weak Detrusor Patients with Benign Prostatic Hypertrophy. ( 26676396 )
2011
43
The early days of prostatectomy for benign prostatic hypertrophy. ( 22132481 )
2011
44
Carvedilol for the treatment of benign prostatic hypertrophy in patients with heart failure? ( 21962427 )
2011
45
Sphaeranthus indicus attenuates testosterone induced prostatic hypertrophy in albino rats. ( 21503998 )
2011
46
[Sexual problems in patients with prostate cancer and those with benign prostatic hypertrophy]. ( 21542379 )
2011
47
Effect of Benincasa hispida fruits on testosterone-induced prostatic hypertrophy in albino rats. ( 24688153 )
2010
48
Association of Polymorphisms in the Prostate-Specific Antigen (PSA) Gene Promoter with Serum PSA Level and PSA Changes after Dutasteride Treatment in Korean Men with Benign Prostatic Hypertrophy. ( 21221201 )
2010
49
Serenoa repens in benign prostatic hypertrophy: analysis of 2 Italian studies. ( 20944533 )
2010
50
Benign prostatic hypertrophy. ( 19737273 )
2009

Variations for Prostatic Hypertrophy

Expression for Prostatic Hypertrophy

Search GEO for disease gene expression data for Prostatic Hypertrophy.

Pathways for Prostatic Hypertrophy

Pathways related to Prostatic Hypertrophy according to GeneCards Suite gene sharing:

(show all 21)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.62 AR EGF EGFR KLK3 PCNA
2 12.58 AR EGF EGFR ESR1 KLK3
3
Show member pathways
12.52 EGF EGFR ESR1 PGR
4 11.95 EGF EGFR PCNA
5 11.66 AR EGFR KLK3
6
Show member pathways
11.64 AR ESR1 PGR
7 11.64 AR CYP19A1 EGFR ESR1
8 11.49 EGF EGFR ESR1
9
Show member pathways
11.42 AR EGF EGFR KLK3
10 11.24 AR KLK3 SRY
11 11.18 CD36 EGFR ESR1
12 11.1 CYP19A1 PGR
13
Show member pathways
11.1 AR ESR1 KLK3
14 11.08 EGF EGFR
15 11.02 EGF EGFR
16
Show member pathways
10.99 EGF EGFR
17 10.97 EGF EGFR
18
Show member pathways
10.96 EGF EGFR ESR1 PGR
19 10.68 EGF EGFR
20 10.03 CYP19A1 ESR1
21
Show member pathways
10.01 EGF EGFR

GO Terms for Prostatic Hypertrophy

Biological processes related to Prostatic Hypertrophy according to GeneCards Suite gene sharing:

(show all 29)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.89 AR EGF EGFR ESR1 SRY
2 transcription initiation from RNA polymerase II promoter GO:0006367 9.77 AR ESR1 PGR
3 positive regulation of protein kinase B signaling GO:0051897 9.76 EGF EGFR ESR1
4 positive regulation of cytosolic calcium ion concentration GO:0007204 9.74 ADRA1A CD36 ESR1
5 response to estradiol GO:0032355 9.69 EGFR ESR1 PCNA
6 positive regulation of DNA repair GO:0045739 9.64 EGFR PCNA
7 positive regulation of vasoconstriction GO:0045907 9.63 ADRA1A EGFR
8 activation of phospholipase C activity GO:0007202 9.62 ADRA1A EGFR
9 ERBB2 signaling pathway GO:0038128 9.62 EGF EGFR
10 regulation of cell motility GO:2000145 9.61 EGF EGFR
11 negative regulation of epidermal growth factor receptor signaling pathway GO:0042059 9.61 EGF EGFR
12 positive regulation of DNA replication GO:0045740 9.6 EGFR PCNA
13 sex differentiation GO:0007548 9.58 AR SRY
14 steroid hormone mediated signaling pathway GO:0043401 9.58 AR ESR1 PGR
15 regulation of peptidyl-tyrosine phosphorylation GO:0050730 9.56 EGF EGFR
16 uterus development GO:0060065 9.55 CYP19A1 ESR1
17 androgen metabolic process GO:0008209 9.54 CYP19A1 ESR1
18 regulation of systemic arterial blood pressure GO:0003073 9.52 AR KLK3
19 prostate gland growth GO:0060736 9.48 AR CYP19A1
20 negative regulation of ERBB signaling pathway GO:1901185 9.46 EGF EGFR
21 regulation of toll-like receptor signaling pathway GO:0034121 9.43 CD36 ESR1
22 positive regulation of MAPK cascade GO:0043410 9.43 ADRA1A AR CD36
23 morphogenesis of an epithelial fold GO:0060571 9.37 AR EGFR
24 positive regulation of phosphorylation GO:0042327 9.33 AR EGF EGFR
25 tertiary branching involved in mammary gland duct morphogenesis GO:0060748 9.32 AR PGR
26 response to lipid GO:0033993 9.13 CD36 EGFR PCNA
27 mammary gland alveolus development GO:0060749 8.8 AR EGF ESR1
28 signal transduction GO:0007165 10.1 ADRA1A AR EGF EGFR ESR1 PGR
29 positive regulation of transcription by RNA polymerase II GO:0045944 10.04 AR EGFR ESR1 PGR SRY

Molecular functions related to Prostatic Hypertrophy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chromatin binding GO:0003682 9.73 AR EGFR ESR1 PCNA
2 lipid binding GO:0008289 9.67 AR CD36 ESR1 PGR
3 ATPase binding GO:0051117 9.5 AR ESR1 PGR
4 steroid hormone receptor activity GO:0003707 9.43 AR ESR1 PGR
5 nitric-oxide synthase regulator activity GO:0030235 9.4 EGFR ESR1
6 enzyme binding GO:0019899 9.35 AR EGFR ESR1 PCNA PGR
7 nuclear receptor activity GO:0004879 9.33 AR ESR1 PGR
8 steroid binding GO:0005496 8.8 AR ESR1 PGR

Sources for Prostatic Hypertrophy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....